| Nicole Mccann, | |
|
1000 S. Fremont Avenue Unit 7, Building A-10, Ste. N101, Alhambra, CA 91803 | |
| (626) 457-4263 | |
| Not Available |
| Full Name | Nicole Mccann |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Location | 1000 S. Fremont Avenue Unit 7, Alhambra, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477297463 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | (* (Not Available)) | Secondary |
| 363A00000X | Physician Assistant | 61236 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Nicole Mccann, 3256 Brookwood Dr, Lafayette, CA 94549-1922 Ph: (925) 818-4278 | Nicole Mccann, 1000 S. Fremont Avenue Unit 7, Building A-10, Ste. N101, Alhambra, CA 91803 Ph: (626) 457-4263 |
News Archive
CytoSen Therapeutics, a private biopharmaceutical company accelerating innovation in Natural Killer cell therapy, today announced it has received a favorable response from the U.S. Food and Drug Administration to its pre-Investigational New Drug meeting package for the proposed Phase 2 trial of CytoSen's adoptive NK cell therapy, CSTD002-NK, for the reduction of relapse in high risk acute myeloid leukemia or myelodysplastic syndrome in patients undergoing haploidentical hematopoietic stem cell transplantation.
Howard Hughes Medical Institute researchers have designed tiny RNA molecules that shut off the gene that causes Huntington's disease without damaging that gene's healthy counterpart, which maintains the health and vitality of neurons.
University of Adelaide researchers are developing a laser system for fast, non-invasive, onsite breath analysis for disease, potentially enabling screening for a range of diseases including diabetes, infections and various cancers in the future.
Celsion Corporation, a leading oncology drug development company, today provided an update on the progress of its pivotal ThermoDox® Phase III "HEAT" trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Following recent regulatory approvals in China, Malaysia, Thailand and the Philippines, the study is now enrolling patients in eleven countries, with the majority of clinical sites located in the Asia Pacific region where HCC is most prevalent.
› Verified 1 days ago
Jessica Lee Palmer, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 1000 S Fremont Ave Ste N10100, Alhambra, CA 91803 Phone: 626-457-4240 | |
Sonya Tang, PA Physician Assistant Medicare: Medicare Enrolled Practice Location: 1024 S Garfield Ave, Alhambra, CA 91801 Phone: 626-289-5181 | |
Courtney Boucher, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 503 N Story Pl, Alhambra, CA 91801 Phone: 626-484-6732 | |
Emily Bahareh Zaghi, PA-S Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 1000 S Fremont Ave Bldg A-11, Alhambra, CA 91803 Phone: 626-457-4240 | |
Mr. Clement Chan, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 220 S 1st St, Alhambra, CA 91801 Phone: 626-281-8663 Fax: 626-281-6318 | |
Emily Denisse Vargas Jimenez, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 3025 Montezuma Ave, Alhambra, CA 91803 Phone: 562-455-8320 | |
Nina Tran, PA Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 1000 S Fremont Ave, Alhambra, CA 91803 Phone: 626-457-4240 |